Status of New Vaccine Introduction - Worldwide September 2016.

Tuesday, 1st of November 2016

MMWR Morb Mortal Wkly Rep. 2016 Oct 21;65(41):1136-1140. doi: 10.15585/mmwr.mm6541a3.

Status of New Vaccine Introduction - Worldwide September 2016.

Loharikar A Dumolard L Chu S Hyde T Goodman T Mantel C.

Abstract

Since the global Expanded Program on Immunization (EPI) was launched in 1974 vaccination against six diseases (tuberculosis polio diphtheria tetanus pertussis and measles) has prevented millions of deaths and disabilities (1). Significant advances have been made in the development and introduction of vaccines and licensed vaccines are now available to prevent 25 diseases (23). Historically new vaccines only became available in low-income and middle-income countries decades after being introduced in high-income countries. However with the support of global partners including the World Health Organization (WHO) and the United Nations Childrens Fund which assist with vaccine prequalification and procurement as well as Gavi the Vaccine Alliance (Gavi) (4) which provides funding and shapes vaccine markets through forecasting and assurances of demand in low-income countries in exchange for lower vaccine prices vaccines are now introduced more rapidly. Based on data compiled in the WHO Immunization Vaccines and Biologicals Database* (5) this report describes the current status of introduction of Haemophilus influenzae type b (Hib) hepatitis B pneumococcal conjugate rotavirus human papillomavirus and rubella vaccines and the second dose of measles vaccine. As of September 2016 a total of 191 (99%) of 194 WHO member countries had introduced Hib vaccine 190 (98%) had introduced hepatitis B vaccine 132 (68%) had introduced pneumococcal conjugate vaccine (PCV) and 86 (44%) had introduced rotavirus vaccine into infant vaccination schedules. Human papillomavirus vaccine (HPV) had been introduced in 67 (35%) countries primarily targeted for routine use in adolescent girls. A second dose of measles-containing vaccine (MCV2) had been introduced in 161 (83%) countries and rubella vaccine had been introduced in 149 (77%). These efforts support the commitment outlined in the Global Vaccine Action Plan (GVAP) 2011-2020 (2) endorsed by the World Health Assembly in 2012 to extend the full benefits of immunization to all persons.